Botulinum Toxin is one of 427 small molecule programs targeting Myofascial Pain Syndrome. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
778 competitors in Osteoarthritis
Botulinum Toxin
Epidiolex
Ilaris
Toradol
Bayer Aspirin
Voltaren
Cataflam
Precedex
Protonix
Catapres
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details